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It’s now cheaper to print color figures in KI
Have you been concerned in the past about the cost of print-
ing color figures in Kidney International (KI)? KI has listened 
to your concerns and is now offering permanently reduced 
pricing for color figures—a flat fee of $500 per printed page, 
no matter how many color figures are on a page. This pricing 
is more affordable for authors and competitive with other top 
scientific journals. We want to make it easier for authors to 
publish the color figures that demonstrate important scien-
tific findings, and our new pricing reflects our commitment to 
achieving this goal.
Aristolochic 
acid tracing and 
uroepithelial 
carcinoma
Endemic (Balkan) nephropathy is 
a chronic tubulointerstitial disease 
frequently accompanied by urothelial-
cell carcinomas. It has been linked to 
exposure to aristolochic acid, a power-
ful nephrotoxin and human carcinogen. 
Aristolactam-DNA adducts concen-
trate and persist in the renal cortex, 
serving as biomarkers for exposure to 
aristolochic acid. Jelaković et al. exam-
ined this stable biomarker in urothelial 
carcinomas of 67 patients in endemic 
Balkan nephropathy areas and 10 from 
nonendemic areas. Detection of the 
aristolactam-DNA adduct proved to be a 
valuable indicator of Balkan nephro pathy 
and the development of carcinomas in 
genetically susceptible individuals. Thus, 
aristolochic acid-DNA adducts can serve 
as biomarkers, providing a role in die-
tary exposure to aristolochic acid in the 
development of endemic nephro pathy 
and carcinomas of the upper urinary 
tract. See page 559.
No benefit from 
combined intensive 
blood pressure and 
glycemic control in 
type 2 diabetics
Decreases both in glucose and in blood 
pressure reduce the risk of several micro-
vascular complications of type 2 diabetes 
mellitus (T2DM), and epidemiological 
analyses suggest that the combined effects 
of blood pressure and glucose control 
may be greater than the benefit of either 
intervention alone. In a subgroup analy-
sis of the Action to Control Cardiovas-
cular Risk in Diabetes (ACCORD) study, 
Ismail-Beigi et al. report that in an elderly 
group of patients, the combined tight 
control of blood pressure and glycemia 
did not provide significant additional 
benefits in terms of multiple end points 
measured. Similarly, microalbuminuria, 
which was significantly reduced by inten-
sification of either blood pressure or 
glycemic control, did not show additional 
benefit from simultaneous intensive 
management. Overall, the disappointing 
results of the various intervention studies 
in elderly patients with T2DM may indi-
cate that ‘late’ intervention may be too 
late to prevent the microvascular com-
plications, which may require preventive 
measures much earlier in the course of 
the disease. See page 586.
Blood pressure and 
dialysis survival
In hemodialysis patients, the relation-
ship between blood pressure and mor-
tality is U-shaped, similar to that in the 
general population. In an observational 
cohort of more than 10,000 hemodi-
alysis patients, Raimann et al. showed 
that both increases and decreases in 
blood pressure were associated with 
worse outcomes, whereas stable blood 
pressure had a survival advantage at 
all levels of systolic and diastolic pres-
sures. Furthermore, the use of cardio-
protective drugs attenuated changes 
and improved survival. This large study 
points out the significance of blood 
pressure changes for hemodialysis sur-
vival and raises the question of how best 
to achieve stable blood pressure in the 
hemodialysis population—by sodium 
restriction and ultrafiltration, by the 
use of cardioprotective drugs, or with a 
combination thereof. See page 548.
